Ye, RG., Ren, GH., Li, HQ. et al. Clinical observation on 30 cases of chronic renal failure treated with Shentekang Capsule and peritoneal dialysisand peritoneal dialysis., CJIM 3, 10–11 (1997). https://doi.org/10.1007/BF02935426
Ye Ren-Gao, Ren Guo-Hui, Li Hui-Qun, et al. Clinical observation on 30 cases of chronic renal failure treated with Shentekang Capsule and peritoneal dialysisand peritoneal dialysis. [J]. Chinese Journal of Integrative Medicine 3(1):10-11(1997)
Ye, RG., Ren, GH., Li, HQ. et al. Clinical observation on 30 cases of chronic renal failure treated with Shentekang Capsule and peritoneal dialysisand peritoneal dialysis., CJIM 3, 10–11 (1997). https://doi.org/10.1007/BF02935426DOI:
Ye Ren-Gao, Ren Guo-Hui, Li Hui-Qun, et al. Clinical observation on 30 cases of chronic renal failure treated with Shentekang Capsule and peritoneal dialysisand peritoneal dialysis. [J]. Chinese Journal of Integrative Medicine 3(1):10-11(1997) DOI: 10.1007/BF02935426.
Clinical observation on 30 cases of chronic renal failure treated with Shentekang Capsule and peritoneal dialysisand peritoneal dialysis
摘要
Objective: To evaluate the effect of Shentekang Capsule (STKC) combined with peritoneal dialysis (PD) in treating chronic renal failure (CRF).Methods: With single-blind
parallel control and random method
60 cases of CRF patients were equally divided into 2 groups: (1) STKC group treated with combined therapy of STKC and PD; (2) control group treated with PD alone. The course of treatment were 1~2 months for both groups. Clinical manifestations
blood urea nitrogen
serum creatinine
total protein and hemoglobin were observed before and after the treatment. Results: Blood urea nitrogen decreased in both groups after treatment as compared with that before treatment significantly (P < 0.05)
but no obvious difference was found between blood urea nitrogen levels of the two groups (P > 0. 05). However
levels of serum total protein and hemoglobin of the STKC group after treatment were higher than those of the control group (P < 0.01). Clinical manifestation in STKC group also showed more improvement after treatment than that in the control group. Conclusion: STKC could improve nutritional state and quality of CRF patient’s life treated with PD.
Abstract
Objective: To evaluate the effect of Shentekang Capsule (STKC) combined with peritoneal dialysis (PD) in treating chronic renal failure (CRF).Methods: With single-blind
parallel control and random method
60 cases of CRF patients were equally divided into 2 groups: (1) STKC group treated with combined therapy of STKC and PD; (2) control group treated with PD alone. The course of treatment were 1~2 months for both groups. Clinical manifestations
blood urea nitrogen
serum creatinine
total protein and hemoglobin were observed before and after the treatment. Results: Blood urea nitrogen decreased in both groups after treatment as compared with that before treatment significantly (P < 0.05)
but no obvious difference was found between blood urea nitrogen levels of the two groups (P > 0. 05). However
levels of serum total protein and hemoglobin of the STKC group after treatment were higher than those of the control group (P < 0.01). Clinical manifestation in STKC group also showed more improvement after treatment than that in the control group. Conclusion: STKC could improve nutritional state and quality of CRF patient’s life treated with PD.